SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3130-3134. Prepublished online as a Blood First Edition Paper on July 29, 2008; DOI 10.1182/blood-2008-05-159632. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-05-159632v1 112/8/3130    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanz, M. A. Articles by Lowenberg, B. Search for Related Content PubMed PubMed Citation Articles by Sanz, M. A. Articles by Lowenberg, B. Related Collections Neoplasia Free Research Articles Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group Miguel A. Sanz1, Pau Montesinos1,2, Edo Vellenga3, Consuelo Rayón4, Javier de la Serna5, Ricardo Parody6, Juan M. Bergua7, Angel León8, Silvia Negri9, Marcos González10, Concha Rivas11, Jordi Esteve12, Gustavo Milone13, José D. González14, Elena Amutio15, Salut Brunet16, J. García-Laraña17, Dolors Colomer12, María J. Calasanz18, Carmen Chillón10, Eva Barragán1, Pascual Bolufer1, and Bob Lowenberg19 1 Hospital Universitario La Fe, Valencia, Spain; 2 Department of Medicine of Universitat Autònoma de Barcelona, Barcelona, Spain; 3 University Hospital, Groningen, The Netherlands; 4 Hospital Central de Asturias, Oviedo, Spain; 5 Hospital 12 de Octubre, Madrid, Spain; 6 Hospital Universitario Virgen del Rocío, Sevilla, Spain; 7 Hospital San Pedro de Alcántara, Cáceres, Spain; 8 Hospital General, Jerez de la Frontera, Spain; 9 Hospital Carlos Haya, Málaga, Spain; 10 Hospital Universitario, Salamanca, Spain; 11 Hospital General, Alicante, Spain; 12 Hospital Clinic, Barcelona, Spain; 13 Fundaleu, Buenos Aires, Argentina; 14 Hospital Insular, Las Palmas, Spain; 15 Hospital de Cruces, Baracaldo, Spain; 16 Hospital Sant Pau, Barcelona, Spain; 17 Hospital Ramón y Cajal, Madrid, Spain; 18 Universidad de Navarra, Pamplona, Spain; and 19 Erasmus University Medical Center, Rotterdam, The Netherlands A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome. Here we analyze treatment outcome of an enlarged series of patients who have been followed up for a median of 65 months. From November 1999 through July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin. Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy. The 5-year cumulative incidence of relapse and disease-free survival were 11% and 84%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P = .019 and P = .04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Schnittger, W. Kern, C. Tschulik, T. Weiss, F. Dicker, B. Falini, C. Haferlach, and T. Haferlach Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML Blood, September 10, 2009; 114(11): 2220 - 2231. [Abstract] [Full Text] [PDF] P. Montesinos, J. Diaz-Mediavilla, G. Deben, V. Prates, M. Tormo, V. Rubio, I. Perez, I. Fernandez, M. Viguria, C. Rayon, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis Haematologica, September 1, 2009; 94(9): 1242 - 1249. [Abstract] [Full Text] [PDF] C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020